Inogen meets expectations in Q4
By HME News Staff
Updated 12:11 PM CST, Tue January 10, 2023
GOLETA, Calif. – Inogen estimates preliminary, unaudited total revenue of $87.5 million to $88.5 million for the fourth quarter of 2022, representing year-over-year growth of 14.5% to 15.8%.
It estimates total revenue of $376.7 million to $377.7 million for the full year, representing year-over-year growth of 5.2% to 5.5%.
“Despite the prevailing macroeconomic pressures and headwinds resulting from our efforts to continue upgrading the operating disciplines in our DTC commercial team, preliminary fourth quarter 2022 results came in within the expectations we had shared during our third quarter earnings call,” said Nabil Shabshab, president and CEO. “We expect productivity to improve in the near-term as the tenure of our DTC team increases and we continue partnering with our B2B channel to manage economic pressures. While we continue to prioritize investments to drive medium to long-term growth, we are also diligently managing operating expenses in support of our plans for long-term profitability.”
Inogen had previously projected total revenue of $87 million to $92 million for the fourth quarter.
The company will issue fourth quarter and full year financial results on Feb. 23.
- Read about Inogen's "health orders" in Q3.
Comments